Related Experiment Video
Updated: May 16, 2026
08:55
Facile Protocol for the Synthesis of Self-assembling Polyamine-based Peptide Amphiphiles (PPAs) and Related Biomaterials
Published on: June 25, 2018
Difluoromethylornithine: the proof is in the polyamines
Joanne M Jeter1, David S Alberts
1Department of Medicine, The University of Arizona Cancer Center, Tucson, Arizona 85719, USA.
Cancer Prevention Research (Philadelphia, Pa.)
|December 11, 2012
Summary
Difluoromethylornithine (DFMO) showed a persistent, though not statistically significant, reduction in nonmelanoma skin cancer (NMSC) in a phase III study. Long-term follow-up confirmed no late toxicity after DFMO treatment discontinuation.
Area of Science:
- Oncology
- Dermatology
- Clinical Pharmacology
Background:
- Nonmelanoma skin cancer (NMSC) is a prevalent malignancy.
- Chemoprevention strategies are crucial for reducing cancer incidence.
- Difluoromethylornithine (DFMO) has been investigated for its potential chemopreventive properties.
Purpose of the Study:
- To evaluate the long-term efficacy of difluoromethylornithine (DFMO) in preventing nonmelanoma skin cancer (NMSC).
- To assess the long-term toxicity profile of DFMO after treatment discontinuation.
- To review DFMO's role as a chemopreventive agent for various cancers.
Main Methods:
- Retrospective review of subjects from a phase III clinical trial.
- Analysis of long-term efficacy data for NMSC prevention.
- Assessment of late-onset toxicity following DFMO treatment cessation.
Main Results:
- Subjects treated with DFMO exhibited a persistent, albeit nonsignificant, decrease in NMSC incidence post-treatment.
- No significant late toxicity was observed after discontinuing DFMO treatment.
- DFMO demonstrated a trend towards reduced NMSC development.
Conclusions:
- DFMO may offer a persistent chemopreventive effect against NMSC.
- DFMO appears to be safe for long-term use with no late-emerging toxicities.
- Long-term follow-up is essential for evaluating cancer chemoprevention agents.
